beta-glucans reduce LDL cholesterol in patients with myasthenia gravis
2013 (English)In: European Journal of Clinical Nutrition, ISSN 0954-3007, E-ISSN 1476-5640, Vol. 67, no 2, 226-227 p.Article in journal (Refereed) Published
We aimed at evaluating whether beta-glucans could improve low-density lipoprotein (LDL) cholesterol levels and/or glycemic control in patients with myasthenia gravis (MG), in whom statins usually have muscle-related side effects. Fifty-nine MG patients participated in the study and received a daily dietary supplement of 3 g of beta-glucans during 8 weeks. Body mass index (BMI) and blood sample analysis of lipid and glucose status were performed before and after 8 weeks intake of beta-glucans. In the 52 patients who completed the study, there was a significant reduction in total cholesterol, LDL, ApoA1 and ApoB (all P<0.003). However, glycemic control and BMI were unaltered. The present study indicates that 8 weeks daily intake of 3 g of beta-glucans significantly reduces total cholesterol, LDL, ApoA1 and ApoB in MG patients. beta-glucans may therefore be of value in improving lipid status in MG patients, without the muscle-related side effects accompanied by statins.
Place, publisher, year, edition, pages
2013. Vol. 67, no 2, 226-227 p.
beta-glucans, LDL cholesterol, myasthenia gravis, glycemic control
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-197408DOI: 10.1038/ejcn.2012.191ISI: 000315016300018OAI: oai:DiVA.org:uu-197408DiVA: diva2:613564